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Objective(s): Intracerebral injection of bone marrow stromal cells (BMSCs) is being investigated as a 
therapeutic tool to prevent Alzheimer's disease (AD). Our aim was to investigate the effects of BMSCs 
by intrathecal injection in AD rat model. 
Materials and Methods:  BMSCs were obtained from the bone marrow of Wistar rat and transplanted 
into AD rat model via intrathecal injection. The rat model had received an injection of β amyloid into 
the hippocampus for histological and immunohistochemical studies.  
Results: Histological examination of the brains in transplanted rats compared to controls 
demonstrated the migration of BrdU-labeled BMSCs from the site of delivery, confirmed the 
differentiation of BMSCs transplanted cells into the cholinergic neurons, and increased number of 
healthy and decreased number of dark neurons. 
Conclusion: Our results showed that BMSCs intratechal administration could be a promising method 
for treatment of Alzheimer’s disease in rat model.  
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Introduction 
Alzheimer Disease (AD) is a complex, destroying, 
and an age-related brain disorder. AD patients endure 
memory loss and cognitive dysfunction. The symptoms 
of AD gradually lead to changes in behavior and 
personality, decrease in cognitive abilities such as 
decision-making and language skills, problems 
recognizing family and friends, and finally loss of the 
ability to perform basic activities of daily living 
including eating, walking, dressing and grooming . 
Currently, there is no effective treatment that can 
significantly delay or stop the progressive brain 
damage in AD. The drugs currently in use treat only 
the symptoms and slow the progression of cognitive 
decline. Stem cells transplantation seems to be a 
promising strategy for treatment of several CNS 
degenerative diseases such as AD.  
There are many types of stem cells in the body, 
which can broadly be divided into embryonic and 
adult (somatic) stem cells. Embryonic stem (ES) cells 
develop into multipotent adult stem cells such as 
neural stem cells (NSCs) and mesenchymal stem cells 
(MSCs). NSCs are very difficult to obtain from adult’s 
brain and so current studies mainly use fetal NSCs, 
which could also generate ethical problems. MSCs 
have self-renewal and a high proliferative capacity 
and have the ability to migrate into damaged organs.  
These cells seem to be able to differentiate                
into multiple cells such as hepatocytes (1), skeletal 
muscle (2) and cardiomyocytes (3). It was found that 
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MSCs derived from bone marrow, adipose tissue and  
umbilical cord blood could be transdifferentiated into  
neuronal cells (4). As embryonic stem cells have the 
potential to generate any cell kind, they are considered 
as an attractive cell source for tissue repair 
applications. Meanwhile, the presence of 
undifferentiated cells in a transplant could result in the 
formation of cardiac teratomas rather than new 
myocardium. Other previous study indicated the effect 
of bone marrow stromal cells on neuronal cells in 
animal model of Alzheimer’s disease (5). In addition, 
BMSCs avoid allergenic rejection , and therefore they 
serve as good choices to treat damaged tissues because 
of such capacities.  
Intrathecal injection is a safe and effective 
strategy for cell transplantation. Jung Yeon Lim et al 
reported migration of hUCB-MSCs to brain and 
differentiation of MSCs into cells by intrathecal 
injection in rat model of cerebral ischemia (6). There 
is little data available on the intrathecal injection of 
stem cells. 
 We have selected intrathecal injection of the 
BMSC by lumbar puncture (LP) for treating AD rat 
model. A previous study used directed injection of 
the BMSCs to brain for treating AD mouse model (7). 
To our knowledge, this is the first study to report the 
effects of intrathecal injection of BMSCs in AD rat 
model. The route of BMSC delivery is the main 
difference between the present study and the 
previous studies. Our aim was to examine the effects 
of BMSCs by intrathecal injection in AD rat model. 
 
Materials and Methods 
In this study, a rat model of AD was created by 
stereotaxic injection of amyloid-β (Aβ) into 
hippocampus via needle of Hamilton syringe (26 
gauge; Hamilton Company, UK). Then, the rats 
received bone marrow stromal cells intrathecally 
and underwent histological examination. Animals 
were housed with free access to food and water in a 
12 hr light/dark cycle and constant temperature of 
22 °C and received human care, as outlined in                  
the guideline for the care and use of laboratory 
animals. This study was confirmed by the Ethical               
Committee of Iran University of Medical Sciences. 
For Histological and immunostaining study, nine 
adult male Wistar rats (250-320 g) were randomly 
divided into 3 groups, with 3 animals in each group. 
In the sham group, a needle of Hamilton syringe was 
stereotaxically inserted into the hippocampus and 
removed without any injection. After 2 weeks, the 
experimental group of AD rat model received the rat 
bone marrow stromal cells via intrathecal injection.  
To create the model of Alzheimer’s disease, 
synthetic amyloid-β protein fragment 1-40 (Sigma-
Aldrich, Germany) was dissolved in deionized water, 
aliquoted and stored at −70 °C until use. At the time 
of application, the frozen aliquots were thawed out 
by incubation at 37 °C. On the day of injection, rats 
were anesthetized with intraperitoneal (IP) injection 
of a cocktail of ketamine hydrochloride (80 mg/kg) 
and xylazine (8 mg/kg) (Sigma-Aldrich, Germany), 
and placed in the stereotaxic frame (Stoelting Co, 
USA). The hippocampus was localized at 3.8 mm 
posterior and ±2.4 mm lateral to the Bregma and 
2.9 mm below the top of the skull according to the 
Paxinos Atlas. Each rat received 5 μl of amyloid-β 
solution in left side and 5 μl in right side over 10 
minutes (8). 
BMSCs were isolated, from the male Wistar rats 
and expanded, as previously described. They were 
previously characterized in our laboratory (9). 
Briefly, both ends of rat femoral bones were cut 
under sterile conditions, and the marrow cavities 
were flushed with phosphate buffered saline (PBS). 
The recovered cells were cultured in low-glucose 
DMEM (Sigma-Aldrich, Germany) supplemented with 
20% fetal bovine serum and penicillin/strepto-mycin 
(100 U/ml and 100 μg/ml, respectively) (both from 
Biosera, France). The cells were subcultured or 
harvested using Accutase (Sigma-Aldrich, Germany) 
and were used freshly without cryopreservation. All 
cultures were incubated at 37 °C in a humidified 
chamber of 5% CO2-95% air.  
In order to enable cell tracing in vivo, BMSCs were 
incubated with 5 μmol/ml of BrdU (Sigma-Aldrich, 
Germany) for 72 hr before transplantation. To 
confirm incorporation of BrdU into the cells, they 
were fixed in 4% formaldehyde for 20 min and 
immunostained with application of 1:500 dilution of 
primary anti-BrdU mouse monoclonal antibody 
(Sigma-Aldrich, Germany) followed by goat anti-
mouse FITC-conjugated secondary antibody (1:400 
dilution factor) (Abcam, Cambridge, UK) as described 
earlier. 
In established models of Alzheimer Disease, the 
cells were intrathecally delivered 14 days after 
injection of amyloid-β using the method described by 
Lim et al (6). Briefly, the rats were anesthetized by 
ketamine/xylazine cocktail (as above) and a small 
longitudinal incision was made over the L3-L4 or L4-
L5 spinous processes. Then, a human neonatal 
lumbar puncture needle (25-gauge) was advanced 
into the spinal canal at the L3-L4 or L4-L5 level, and 
1 × 106 BMS cells (in 20 μl PBS) were injected into 
the cerebrospinal fluid (CSF) over 30 sec. Eight 
weeks after the stereotaxic surgery, all rats were 
euthanized by 150 mg/kg of ketamine and perfused 
through the ascending aorta with 50 to 100 ml of 
0.9% saline followed by 100 to 150 ml of fixative 
solution containing 4% formaldehyde in 0.1 M 
phosphate buffer solution (PBS, pH 7.4) and 100 ml 
of 0.1 M PBS, respectively. The brains were removed 
from the skulls and fixed in 4% formaldehyde for 24 
hr. Following routine paraffin processing, serial 
sections of the brain were cut coronally at 5 μm 
thickness in a rotary microtome.  
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Figure 1. Immunohistochemical staining for tracing of BrdU-labeled cells; (A) the brown stain of the nuclei of BrdU+ cells are indicated 
by black and white arrows in cortex (scale bar 200 μm), a BrdU+ nucleus is shown by a higher magnification at the left upper corner 
(B) BrdU+ BMS cells in thalamus (white arrow) and dentate gyrus (Black arrow) (scale bar 500 μm) (C) BrdU-labeled BMS cells are 
observed in subiculum (black arrow), cortex (black arrow heads) and dentate gyrus (white arrow) (scale bar 2 mm) 
 
 
Amyloid-β was stained with Congo red. On the other 
hand, Nissl staining with 1% cresyl violet was used for 
staining of neurons. Three periodic Nissl-stained 
coronal brain sections were used for cell counting 
under the magnification of ×40 using a light microscope 
(Olympus Optical Co, Ltd, Japan). Non-basophilic 
neurons with pale nuclei were counted as normal 
neurons while those with massive shrunken, 
hyperbasophilic features were counted as injured and 
abnormal neurons (so-called dark neurons). In each 
section, 3 fields in CA1, 1 field in CA2, 2 fields in CA3 
and 2 fields in CA4 were counted.  
Three periodic coronal brain sections (from ever 
animal) were used for immunostaining methods as 
well. But for these methods, our aim was the tracing 
of Brdu and CHAT markers in the brain of treated AD 
group. (No Statistical analysis).  
EnVison system’s HRP-based immunostaining 
method (Dako, Denmark) was used for tracing of BrdU-
labeled BMSCs in the histological sections. The coronal 
brain sections were used for this method, and observed 
under the magnification of ×40 using a light microscope 
(Olympus Optical Co, Ltd, Japan). After antigen retrieval 
at 60 °C for 60 min and blocking of endogenous 
peroxidase activity, the sections were incubated with 
anti-BrdU mouse monoclonal antibody (1:400) (Sigma-
Aldrich, Germany). The sections were stained with 
hematoxylin.  
To evaluate the differentiation of labeled BMSCs 
into the cholinergic neurons, a double immune-
fluorescence staining for BrdU and choline 
acetyltransferase (ChAT) has been performed after 
antigen retrieval as above. Primary antibodies were 
diluted at 1:200 for anti-BrdU mouse monoclonal 
antibody (Sigma-Aldrich, Germany) and at 1:500 for 
anti-ChAT rabbit polyclonal antibody (Abcam, 
Cambridge, UK). The secondary antibody for detection 
of anti-BrdU was conjugated with Texas Red, and that 
for detection of anti-ChAT was conjugated with FITC 
(both from Santa Cruz, Germany). DAPI (Sigma, 
Germany) was used for counterstaining the nuclei. The 
coronal brain sections were used for this method, and 
observed under the magnification of ×40 using a 
fluorescence microscope. 
One way ANOVA with Bonferroni Post hoc test 
was used for comparison of the counts of normal and 
dark neurons in sections of hippocampus in the 
sham, untreated and treated Alzheimer’s disease 
groups. Significant level was set at P< 0.05.  
 
Results 
Histological examination of the brains 
demonstrated migration of BrdU-labeled BMS cells 
from the site of delivery, increased the number of 
healthy and decreased the number of dark neurons 
following BMS cells transplantation, and showed 
differentiation of transplanted cells into the cholinergic 
neurons.  
Immunocytochemical staining of BMS cells before 
transplantation confirmed incorporation of BrdU 
into these cells. Congo red staining showed 
amyloidal-β deposits in the CA1 region of 
hippocampus, dentate gyrus, thalamus and cortex of 
untreated rat models of established AD. No amyloid 
deposition could be detected in the brains of rats in 

















Figure 2. In vivo differentiation of BMS cells into cholinergic 
neurons; fluorescent staining for BrdU (red), ChAT (green) 
and nuclei (DAPI – blue) in a CA1 section of hippocampus. (A) 
green fluorescence represents ChAT+ cholinergic neurons, (B) 
DAPI staining of cell nuclei, (C) BrdU+ cells representing BMS 
cells migrated into the brain and (D) Merged image of the 
double staining for ChAT, nuclei and BrdU confirming 
differentiation of some BMS cells into cholinergic neurons 
(white arrow). The cell indicated by white arrow is shown 
with higher magnification in the inset. The purple color of the 
nucleus is the result of blue and red merger. All the scale bars 
are 200 μm  
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Table 1. Comparison of the counts of normal and dark neurons in sections of hippocampus in three experimental groups of sham, and 
untreated and treated rats with Alzheimer disease 
 
Sections Groups 
Normal neurons Dark neurons 
Counts 95% CI P-value*  Counts 95% CI P- value* 
CA1 
Sham vs U-AD 
28.00±14.86 vs 
15.25±14.96 
1.66 to 23.84 < 0.05  
8.58±13.31 vs 
27.83±17.50 
-30.70 to -7.80 < 0.05 
Sham vs T-AD 
28.00±14.86 vs 
46.29±17.29 
-29.38 to -7.20 < 0.05  
8.58±13.31 vs 
8.42±17.32 
-11.28 to 11.62 ns 





< 0.05  
27.83±17.50 vs 
8.42±17.32 
7.97 to 30.87 < 0.05 
CA2 
Sham vs U-AD 
22.38±13.22 vs 
25.88±20.36 
-23.14 to 16.14 ns  
7.00±9.17 vs 
26.13±26.31 
-44.93 to 6.68 ns 
Sham vs T-AD 
22.38±13.22 vs 
25.88±9.74 
-23.14 to 16.14 ns  
7.00±9.17 vs 
16.00±19.94 
-34.80 to 16.80 ns 
U-AD vs T-AD 
22.88±20.36 vs 
25.88±9.74 
-19.64 to 19.64 ns  
26.13±26.31 vs 
16.00±19.94 
-15.68 to 35.93 ns 
CA3 
Sham vs U-AD 
10.81±12.24 vs 
5.19±5.44 
-5.03 to 16.28 ns  
18.56±16.79 vs 
29.13±15.75 
-25.82 to 4.70 ns 
Sham vs T-AD 
10.81±12.24 vs 
21.75±6.17 
-21.60 to -0.28 < 0.05  
18.56±16.79 vs 
20.75±19.34 
-17.45 to 13.07 ns 
U-AD vs T-AD 
5.19±5.44 vs 
21.75±6.17 
-27.22 to -5.90 < 0.05  
29.13±15.75 vs 
20.75±19.34 
-6.89 to 23.64 ns 
CA4 
Sham vs U-AD 
4.31±9.94 vs 
3.94±6.42 
-9.24 to 9.99 ns  
19.75±13.60 vs 
28.81±21.94 
-23.91 to 5.788 ns 
Sham vs T-AD 
4.31±9.94 vs 
19.44±14.78 
-24.74 to -5.51 < 0.05  
19.75±13.60 vs 
16.56±13.74 
-13.01 to 17.18 ns 
U-AD vs T-AD 
3.94±6.42 vs 
19.44±14.78 
-25.11 to -5.89 < 0.05  
28.81±21.94 vs 
16.56±13.74 
-3.95 to 26.24 ns 
 
* One way ANOVA with Bonferroni post-hoc test  





Nissl staining of coronal brain sections showed 
numerous normal and dark neurons in the 
hippocampus of the rats under the experiment. 
Statistical analysis (Table 1 and 2) indicated that in 
CA1, the counts of normal neurons were significantly 
higher in sham group compared with untreated and 
treated AD groups. The number of normal neurons in 
treated AD group with the BMSC was also 
significantly higher compared with the untreated AD 
group (P<0.05). In CA2 however, the number of 
normal neurons did not reveal any significant 
difference between the compared groups. In CA3 and 
CA4, the counts of normal neurons did not show any 
significant difference between sham and untreated 
AD group. However, the number of normal neurons 
in CA3 and CA4 were significantly higher in treated 
AD group (with BMSC) compared with both sham 
and untreated AD groups. On the other hand, the 
number of dark neurons was significantly higher in 
untreated AD group in CA1 compared with sham and 
treated AD groups (P<0.05). The number of dark 
neurons showed no significant change in other 
comparisons.  
Tracing of BrdU-labeled cells in the treated group 
showed that intrathecally delivered BMS cells 
accommodated in the brain regions including dentate 
gyrus, subiculum and thalamus cortex (Figure 1).             
On the other hand, double immunofluorescent staining 
for BrdU and ChAT showed that intrathecally 
administered BMS cells were differentiated into 
cholinergic neurons (Figure 2).  
 




Our study showed that the BMSC implantation 
increase the number of healthy cells and eliminate β 
amyloid deposition in treated group. Localization of 
BrdU+ BM-MSCs in the brain by immune-histochemical 
and immune fluorescent staining in this study, 
confirmed their migration into brain. In addition, BM-
MSCs differentiation into cells with positive staining for 
ChAT neural marker (in immune fluorescent staining) 
indicated the survival of the implanted cells. BMSCs 
may be differentiated to neuronal cells or induced 
neurogenesis of endogenous neural stem cells (5). 
BMSCs may improve cognitive function of learning in 
AD by expressing ChAT. This study also confirmed the 
differentiation of the BMSCs to ChAT neural cells in AD 
Rat CA1 Groups Mean SD 
Sham 28 14.86 
Alzheimer 15.25 14.69 
Treatment 46.29 17.29 
Rat CA2    
Sham 22.38 13.22 
Alzheimer 25.88 20.36 
Treatment 25.88 9.74 
Rat CA3    
Sham 10.81 12.24 
Alzheimer 5.19 5.44 
Treatment 21.75 16.17 
Rat CA4    
Sham 4.31 9.94 
Alzheimer 3.94 6.42 
Treatment 19.44 14.78 
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rat model after directed injection of BM-MSCs (8). 
Another study reported that human NSCs (expressing 
ChAT) have lesion-tropic property and improve 
cognitive function of learning by increasing 
acetylcholine level in deficit model rats with 
hippocampal injury (10).  
Direct  injection of stem cell into brain in AD and 
other neurodegenerative animal models has been 
reported before (11). However, this method (directed 
injection) is often impractical for patients with clinically 
severe conditions (6). Jung Yeon Lim et  al reported that 
both intravenous and intrathecal administration of cells 
demonstrated similar effects for neurological recovery 
in ischemic stroke regardless of migration and grafting 
difference within the ischemic brain.  
They reported that many more grafted cells 
survived in animals after intrathecal administration 
when compared with animals after intravenous 
administration, due to the comparative insufficiency of 
the stem cell dosage in intravenous method. On the 
other hand, applying a large number of cells has some 
restrictions in human clinical trials.  
Generally, the number of neurons determines the 
functional capacity of the brain or any particular neural 
structure (12). Our statistical analysis also shows the 
neuronal loss in the hippocampus of AD compared to 
sham group. This was mainly expressed by a significant 
decrease of neuronal density, especially in the CA1 area 
as the major site of neuronal loss in AD hippocampus, 
which is reported in reference to the degeneration of 
neurons in AD models. A significant reduction of 
neuronal density, especially in the CA1 and CA3 areas 
was also shown in AD with the most prominent 
decrease in CA1 area in other studies. Besides, the 
neuronal loss was detected in the CA2 and CA4 areas of 
AD group, although it was not statistically significant. 
According to our findings, the treatment group 
shows an increase of healthy neuron in CA1, CA3 and 
CA4 (but not in CA2) compared to AD group (P<0.05). 
To date, many experiments confirm the 
interconnected networks corresponding to the 
anatomical sub-fields of dentate gyrus (DG), CA3 and 
CA1 (the hippocampal circuit diagram). This is perhaps 
in conformity to this pattern. More experimental 
studies predicted the important announcement of the 
CA2 in neurodegenerative diseases such as AD (13). In 
agreement to previous studies, the findings of this study 
indicate consistent results in the AD model.   
Here we show in the treatment group that beta 
amyloidal plaques might be eliminated, which could be 
confirmed via a meta-analysis. 
 Previous studies confirmed that BMSCs migration 
by directed method into brain, reduces β amyloid 
deposition (4, 14). It promotes neurogenesis of 
endogenous neural stem cells in the hippocampus of 
AD rat, and shows some therapeutic effects in 
neurodegenerative diseases. Shin JY et al reported that 
MSCs significantly enhance autolysosome formation 
and clearance of Aβ in AD models, which may increase 
neuronal survival against Aβ toxicity (15). 
Generally addressing to the results of this study, 
further experiments are necessary for confirmation of 
neurogenesis and of ChAT influences on learning by 
intrathecal injection of BMS cells in AD.  
 
Conclusion 
Our finding led us to hypothesize that BMSCs 
injection via intrathecal method in AD rat model 
migrated into brain, survived and differentiated into 
ChAT-like neuron cells, decreased neurotoxicity of beta 
amyloid, increased the number of neuron cells and it 
may be a clinically feasible route of providing less 
invasive transplantation trophy in Alzheimer’s disease. 
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